AIIMS begins human trials of Covid vaccine ‘Covaxin’ today developed by Bharat Biotech
AIIMS has started human trials of the coronavirus vaccine ‘Covaxin’ today. Bharat Biotech started its trial on humans on July 15.
New Delhi: The human trial of the coronavirus (Covid-19) vaccine ‘Covaxin’ developed by Bharat Biotech, a pioneer in the field of biotechnology, has started at All India Institute of Medical Sciences (AIIMS) here on Monday.
Bharat Biotech began the trial of the vaccine Covaxin on humans on July 15. The human trial of this vaccine has also started in PGI and AIIMS Patna, Rohtak, Haryana. Today, it started in AIIMS New Delhi. The clinical trial is being led by Dr. Sanjay Rai of the Department of Community Medicine and will be assisted by Professor Puneet Mishra.
AIIMS director Dr. Randeep Guleria said the trial of the vaccine would be conducted on 1,125 people, of which the effects of the vaccine would be tested on 375 people in the first phase. The vaccine is to be tested on 100 people during the first phase in AIIMS, New Delhi. When the vaccine proves to be safe in the first phase, then the second phase will begin. The target of the first phase is whether or not this vaccine is safe, how effective its dose will be, and what dose would the patient need? The first phase of the trial is to be conducted on people between 18 and 55 years old.
In the second phase, trials of three forms of Covaxin will be clinically conducted. Phase II trial will be relatively large, consisting of 750 candidates. It will only be tested on humans who are completely healthy and not infected with the corona. Pregnant women will not be taken in the trail. Subjects between the age of 12 and 65 will participate in this phase.
The ‘Covaxin’ vaccine is being developed in collaboration with the Indian Institute of Medical Research (ICMR) and the National Institute of Virology in Pune. The Drug Controller General has given its approval for trial on humans.